Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7751 | S26948 |
| Selective PPARγ agonist (EC50 = 8.83 nM). Drives normal adipocyte differentiation and exhibits a lipid-lowering effect; reduces atherosclerosis in E2-KI mice. Displays antidiabetic properties and improves hepatic insulin sensitivity in intralipid-infusion (IL) rats. | |
| BCC7752 | N-Nonyldeoxynojirimycin |
| Glucosidase inhibitor (IC50 values are 0.42 and 8.4 μM for acid α-glucosidase and α-1,6-glucosidase respectively). Inhibits liver glycogen breakdown in vivo. Also acts as a chemical chaperone; chaperones β-Glu folding at neutral p.H. allowing the stabilized enzyme to transit from the endoplasmic reticulum to the golgi, enabling proper trafficking to the lysosome. | |
| BCC7760 | K858 |
| Selective ATP-uncompetitive mitotic kinesin Eg5 inhibitor (IC50 = 1.3 μM). Induces mitotic arrest, caspase-3 activation and cell growth inhibition in HCT116 cells. Displays no effect on microtubule dynamics. Preferentially induces mitotic arrest in cancer cells. | |
| BCC7761 | Endoxifen |
| Estrogen receptor α (ERα) ligand; potent antiestrogen. Metabolite of tamoxifen. Primary metabolite responsible for the effectiveness of tamoxifen in ER-positive breast cancer. | |
| BCC7762 | AS 1949490 |
| Selective SHIP2 (SH2 domain-containing inositol 5'-phosphatase 2) inhibitor (IC50 values are 0.34 μM and 0.62 μM for mouse and human respectively); displays approximately 30-fold affinity for SHIP2 over SHIP1. Increases insulin-induced phosphorylation of Akt in L6 myotubules. Stimulates activation of glucose metabolism; regulates gluconeogenesis in vitro and in vivo and exhibits antidiabetic effects. | |
| BCC7769 | RN 1747 |
| Selective TRPV4 agonist (EC50 values are 0.77, 4.0 and 4.1 μM for hTRPV4, mTRPV4 and rTRPV4 respectively). Displays selectivity over other TRP channels (EC50 values are 0.77, >30, >30 and >100 μM for TRPV4, TRPM8, TRPV3 and TRPV1 receptors respectively). Also antagonizes TRPM8 at relevant concentrations (IC50 = 4 μM). | |
| BCC7770 | RN 1734 |
| Selective TRPV4 antagonist (IC50 values are 2.3, 3.2 and 5.9 μM for hTRPV4, rTRPV4 and mTRPV4 receptors respectively). Displays selectivity for TRPV4 over other TRP channels (IC50 values are 2.3, >30, >30 and >100 μM for TRPV4, TRPV3, TRPM8 and TRPV1 respectively). Blocks TRPV4-mediated arteriole vasodilation and increases myogenic tone ex vivo. | |
| BCC7771 | Pyr3 |
| Selective antagonist of the canonical transient receptor potential channel 3 (TRPC3). Inhibits TRPC3-mediated Ca2+ influx (IC50 = 0.7 μM) and suppresses activation of nuclear factor of activated T cells (NFAT). Inhibits hypertrophic responses in cardiomyocytes. | |
